Approval · Notice of Compliance 26344 · 2021
BENLYSTA: Notice of Compliance 26344
Issued July 29, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26344
- Date
- July 29, 2021
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: Benlysta (belimumab) is indicated in addition to standard therapy for: treatment of active lupus nephritis in adult patients.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BENLYSTA | Not yet assigned | — |